Invert Bioprocess is proud to announce that it has successfully raised $20,100,000 in its latest funding round—a transformative milestone for a company at the forefront of revolutionizing bioprocessing software. Specializing in comprehensive solutions for biopharma, synthetic biology, and CDMOs, Invert’s cutting-edge technology provides full transparency into every facet of bioprocess data, spanning from the laboratory bench to full-scale production. This infusion of capital will accelerate the company’s mission to streamline data management processes across the bioprocessing spectrum by eliminating cumbersome manual data entry, enhancing traceability from upstream operations to final formulations, and empowering teams with actionable insights. The new funds will be strategically invested in scaling their software platform, driving technology innovation, and expanding market reach—all while strengthening the company’s research and development capabilities to stay ahead in an increasingly competitive industry. With this investment, Invert is set to deliver even greater value to its customers by enabling real-time collaboration amongst interdisciplinary teams and global partners, ensuring that every stakeholder has access to the most accurate, up-to-date process data. As the bioprocessing landscape continues to evolve, Invert’s commitment to transforming complex data into clear, actionable intelligence stands to redefine operational efficiency and decision-making throughout the industry. This announcement not only marks a significant financial vote of confidence in Invert’s vision and capabilities but also reinforces the company’s role as a trusted partner dedicated to driving innovation and excellence in bioprocessing worldwide.

Invert Bioprocess Secures $20.1M Seed Funding to Revolutionize Bioprocess Data Transparency
Get the full Invert Bioprocess company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
neubond
Neubond specialises in personalised home rehabilitation devices for stroke patients to address their mobility constraints. Our innovative devices establish a direct connection to the patient’s body, seamlessly integrating effective therapy into their daily lives.
$2.0M Seed
today

Pathway Labs
Pathway Labs is a seed stage software company on a mission to help more individuals realize economic opportunity through the pursuit of vocational training. We do this by modernizing the workflows involved in the student lifecycle from admissions to enrollment and academics to job placement.
$8.5M Seed
today

Nanomedicine Lab
The Nanomedicine Lab is a multidisciplinary research group based at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and affiliated with the Institute of Neurosciences at the Faculty of Medicine of the Universitat Autònoma de Barcelona (UAB) all located in Barcelona, Spain. The Nanomedicine Lab is also an affiliate member of the Centre for Nanotechnology in Medicine at the Faculty of Biology, Medicine and Health of the University of Manchester in the United Kingdom which is fostering expertise and knowledge in innovative nanotechnologies for a broad range of medical applications. The Nanomedicine Lab research portfolio includes the discovery and preclinical development of nanomedicine constructs based on novel, advanced nanomaterials of synthetic and biological nature. Great emphasis is placed at the interplay between in vitro and in vivo studies and how rationally designed and engineered nanoscale platforms can be safely translated into clinically effective therapeutics and diagnostics, with a particular interest in oncology and neurology.
$870.0M Series d
today

Polysight
Regulatory compliance in healthcare is fragmented, manual, and a massive drain on time and resources. Healthcare systems spend $39 billion annually on compliance. This takes away resources from patient care and impacts the bottom line. Polysight is working to address this problem through a single, cohesive AI-enabled compliance management platform. We aspire to a future where healthcare regulatory compliance is a shared, transparent process, enabled by our AI platform as the definitive source of truth for every compliance obligation affecting health systems.
$1.5M Seed
today

Alan
Alan is the prevention insurance. Founded in 2016, Alan is reinventing what health insurance should be: not just covering your employees when they get sick, but helping keep them healthy every day. Alan pairs exceptional insurance and service quality with innovative health services (a virtual clinic available 7 days a week, a medically supervised AI assistant, gamified prevention, no out‑of‑pocket eyewear), which provide access to affordable, personalized care and make prevention effective. All in a single, integrated experience designed for maximum employee adoption and simplified administration for your HR teams, with no intermediaries. Alan also offers plans dedicated to self‑employed workers and public‑sector employees. Over 1 million members trust Alan, across more than 37,000 companies and organizations of all sizes and sectors. With 800+ employees, Alan operates in France, Spain, Belgium, and Canada.
$557.5M Series e
today
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() neubond United Kingdom | Seed | $2.0M | today |
| 2 | ![]() Pathway Labs United States | Seed | $8.5M | today |
| 3 | ![]() Polysight United States | Seed | $1.5M | today |
| 4 | ![]() Trase | Seed | $107.0M | today |
| 5 | ![]() Kalipso Spain | Seed | $3.2M | today |

